Research Article

Archives of Pharmacal Research

, Volume 36, Issue 8, pp 1023-1028

First online:

Methoxyphenylcipro induces antitumor activity in human cancer cells

  • Nizar M. MhaidatAffiliated withDepartment of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science & Technology Email author 
  • , Amjad M. QandilAffiliated withJordan University of Science & TechnologyKing Saud Bin Abdulaziz University for Health Sciences
  • , Qosay A. Al-BalasAffiliated withJordan University of Science & Technology
  • , Mohammad A. HassanAffiliated withJordan University of Science & Technology
  • , Saied A. JaradatAffiliated withJordan University of Science & Technology
  • , Ahmad M. MatalkahAffiliated withJordan University of Science & Technology
  • , Rick T. ThorneAffiliated withFaculty of Health, The Newcastle University

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


To examine the antitumor activity of a new derivative of ciprofloxacin called methoxyphenylcipro (CMPP). Cell viability was assessed using the MTT assay and apoptotic cells and reactive oxygen species were evaluated using flow cytometry. Results revealed that CMPP induces antiproliferative activity against breast cancer cells and melanoma and to a lesser extent against colorectal cancer cells. Interestingly, compared to ciprofloxacin, CMPP-induced a selective cytotoxicity against human cancer cells but not human normal fibroblasts. The potential of CMPP to inhibit cellular growth in MD-MB-486 breast cancer cells and MV3 melanoma cells was largely due to induction of caspase-dependent apoptosis, as confirmed by caspase-3 activation and cleavage of its substrate PARP. In addition, results indicated that CMPP-induced apoptosis is mediated by generation of reactive oxygen species. These findings revealed that CMPP has a selective antitumor activity against cancer cells and warrants further clinical evaluation.


Apoptosis Breast cancer CMPP Colorectal cancer Melanoma